Orbis names a new CEO after its $1.4bn billion Novo Nordisk deal, but can AI-designed macrocycles replace injections?
Orbis names Joanne Smith-Farrell CEO after its $1.4 billion Novo Nordisk partnership. The next test is advancing AI-designed oral macrocycles.